arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Edgewise Therapeutics, Inc.

EWTX
$43.49 ▼ -0.84 (-1.89%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Edgewise Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -8.7%
FCF / Share $-0.40
Trailing P/E
Price / Book 9.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-49.01M
↓ -20.1%
FCF / Share Free cash flow per share
$-0.40
— -0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters